Compare SNY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNY | MRNA |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7B | 91.2B |
| IPO Year | 2001 | 2018 |
| Metric | SNY | MRNA |
|---|---|---|
| Price | $46.64 | $196.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 23 |
| Target Price | $54.92 | ★ $164.53 |
| AVG Volume (30 Days) | 4.2M | ★ 11.3M |
| Earning Date | 10-30-2026 | 11-06-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $3.97 | $24.09 |
| Revenue Next Year | $6.77 | $11.33 |
| P/E Ratio | $6.14 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $39.07 | $23.55 |
| 52 Week High | $50.61 | $280.80 |
| Indicator | SNY | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 41.43 |
| Support Level | $45.95 | $181.02 |
| Resistance Level | $48.57 | $254.48 |
| Average True Range (ATR) | 0.86 | 18.33 |
| MACD | -0.20 | -7.45 |
| Stochastic Oscillator | 40.49 | 5.92 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.